Answers are grounded in this paper and cite their sources.
, and significantly improved the platelet count compared with that in the VCR group (P < 0.05); moreover, it reduced the systemic toxicity and peripheral neurotoxicity of vincristine. The possible mechanism was that CD41-VLP could precisely target M1 macrophages in spleen and liver tissues through FcγR, thus reducing the platelet destruction caused by M1 macrophages. Therefore, CD41-VLP provides a new targeted therapy for ITP treatment.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: